Patents for CombiCult, combinatorial cell culture platform technology, have been granted in the U.S. and Japan, according to Plasticell, a biotechnology company specializing in high throughput technologies for directed stem cell differentiation.
CombiCult breaks the bottleneck in stem cell R&D programs—the discovery of optimized stem cell differentiation protocols. CombiCult also allows scientists to develop custom cell culture media (e.g. GMP compatible stem cell expansion media for cell therapy), create high value cell lines for toxicity testing in the pharmaceutical, cosmetic and nutrition industries, and to increase yield and decrease cost of bioprocess manufacturing.
“Plasticell's proprietary technology breaks the major bottleneck in current stem cell research,” commented Sir Martin Evans FRS, a founding member of Plasticell’s scientific advisory board and recipient of the Nobel prize for the isolation of embryonic stem cells. “Having followed CombiCult's development for almost a decade, I am delighted that the importance of this revolutionary technology is now being recognized through multiple industry awards and patents.”
Patents covering CombiCult have now been issued in the U.S., Europe, Japan, Australia and Singapore.